Saad ED, Squifflet P, Burzykowski T, et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncology 2019; 20: 361–70—In the summary of this Article, the fourth sentence of the findings section should read “Subgroups defined by nodal status and hormone receptor status yielded qualitatively similar results.” This correction has been made to the online version as of March 1, 2019, and the printed Article is correct.
[Corrections] Correction to Lancet Oncol 2019; 20: 361–70
Leggi l'articolo originale